Policy / Pricing UniQure, Replimune shares rise as FDA’s Makary exits, but path forward unchanged BioSpaceAfter devastating regulatory setbacks last year, shares of uniQure and Replimune rose on the news that FDA Commissioner Marty Makary is leaving.Read full story pharminent May 13, 2026 (Last updated: May 13, 2026) BioSpace After devastating regulatory setbacks last year, shares of uniQure and Replimune rose on the news that FDA Commissioner Marty Makary is leaving. Read full story Post navigation Previous: Assertio accepts new buyout bid; AI biotech Isomorphic banks $2BNext: FDA’s leadership void leaves biotech with renewed ‘uncertainty’ Related Stories Policy / Pricing Mid-cap biotechs join Trump’s latest round of drug pricing deals pharminent September 1, 2026 Policy / Pricing MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones pharminent August 27, 2026 Policy / Pricing MFN affecting Swiss medicines access, says Interpharma pharminent August 13, 2026